drugset / Trial / NCT01327014

Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia

NCT01327014

Phase 2 Completed 116 enrolled Beijing Peking University WBL Biotech Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to demonstrate the efficacy of XueZhiKang to improve plasma lipid profile, as compared to placebo, in outpatients with hyperlipidemia.

Timeline

Start
2011-04
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Xuezhikang Traditional medicine (herbal / TCM) 1200 mg
Subject Xuezhikang Traditional medicine (herbal / TCM) 2400 mg

Indications